ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Sequoia China-backed biopharma company files for $100m U.S. IPO

Structure Therapeutics developing drugs targeting a wide range of chronic diseases

Headquartered in California, Structure Therapeuticshas has research and development operations in China. (Source image from Structure Therapeutics website)

CEBU, Philippines -- Structure Therapeutics, a clinical-stage biopharmaceutical company backed by venture capital investors, including Sequoia Capital China, has filed to raise $100 million in an initial public offering in the U.S.

The drugmaker, headquartered in California with research and development operations in China, is looking to list its American depositary shares (ADS) on Nasdaq under the symbol GPCR, according to its heavily redacted filing.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more